Organon

Inception Fertility™ 2024 Annual Physician Summit: A Celebration of Collaboration, Patient Dedication, and Advancements in Fertility Research

Retrieved on: 
Thursday, March 14, 2024
Diamond, Health, Prelude, Organon, Learning, Merck Serono, Ferring Pharmaceuticals, Physician, Patient, Mental health, Patient experience, Reproductive medicine, Fertility, Labcorp, Inception, The Cooper Companies, Summit, Family, Parent, Nursing

HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.

Key Points: 
  • Global fertility leader's annual summit brings together physicians, team members across Inception's expansive family of brands
    HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility ™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.
  • This included two full days of learning, team building, collaborating, and the field of reproductive medicine.
  • Panel sessions covered topics related to mental health in fertility care, groundbreaking research studies, and using technology to drive the patient and employee experience, among others.
  • The 2024 Patient Experience Awards included the Patient Experience Outstanding Practice Award, Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, and Patient Experience Tenet Leaders Awards.

Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Saturday, March 9, 2024
EMA, Week, Psoriasis, Committee, SB5, Political moderate, Ustekinumab, Organon, FDA, Food, Samsung, BLA, Trial of the century, AAD, Safety, CHMP, Pharmacokinetics, Abstract, Biologics license application, American Academy, Novartis, Interchangeability

“We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.

Key Points: 
  • “We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.
  • The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and prefilled autoinjector of HADLIMA was approved in August 2022.
  • The study showed that efficacy, safety, and immunogenicity between the three arms were comparable up to Week 52.
  • Details of the Samsung Bioepis’ abstracts are as follows:
    Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Retrieved on: 
Monday, December 18, 2023
Health, Other Consumer, Consumer, Women, Other Health, Pharmaceutical, Biotechnology, Galcanezumab, Sale, Norton Lilly International, Vomiting, Woman, Migraine, NYSE, Headache, Disease, Patient, Light, OGN, Eli Lilly and Company, Nausea, Disability, Central nervous system, CGRP, Education, Pharmaceutical industry, Lilly, Organon

RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Key Points: 
  • RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
  • “This commercialization agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our Established Brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine,” said Kevin Ali, Organon CEO.
  • “We are confident this collaboration with Organon will help even more people throughout Europe gain access to our innovative migraine treatments.”
    Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality and RAYVOW in Europe.
  • Total consideration to be paid to Lilly includes an upfront payment of $50 million and sales-based milestone payments.

MATTER opens applications for accelerator focused on reducing maternal mortality in the U.S.

Retrieved on: 
Tuesday, December 12, 2023
Pharmaceutical, Health Technology, Health Insurance, Research, Parenting, Healthcare Reform, Public Policy, Government, Hospitals, Baby, Maternity, Fitness & Nutrition, Clinical Trials, University, Education, Biotechnology, Women, Professional Services, Health, Practice Management, Vitamins, Supplements, General Health, Science, Consumer, Social Services, Other Health, Health Care Service Corporation, Infant, Parkview Health, Incidence, Prenatal care, BayCare Ballpark, Mortality, Pregnancy, Mentorship, Death, Labs, HCSC, Mother, Risk, Organon, Dietary supplement

MATTER , the premier healthcare incubator and innovation hub, has opened applications for the second 51 Labs , an accelerator focused on women’s health.

Key Points: 
  • MATTER , the premier healthcare incubator and innovation hub, has opened applications for the second 51 Labs , an accelerator focused on women’s health.
  • This year’s program focuses on preventing maternal mortality in the U.S. before, during and after birth and receives support from Health Care Service Corporation , Laerdal Million Lives Fund , BayCare , Parkview Health , University of Chicago Medicine , Organon and Stryker .
  • While all ages and races saw an increase in maternal mortality in 2021, many inequities still exist due to a variety of factors, including but not limited to access to quality care, socioeconomic status, race and education level.
  • The second cohort of the 51 Labs accelerator will address the question:
    How can we prevent maternal mortality in the U.S. before, during and after birth?

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 21, 2023
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, EST, OGN, NYSE, Conference, Piper Sandler Companies, Pharmaceutical industry, Organon

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

Retrieved on: 
Thursday, November 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pfizer, Integra, Chemistry, MTX, Kyowa Kirin, University College Utrecht, Patient, Multimedia, Isoti, FDA, Alliance Manchester Business School, IPO, MBA, University, Partnership, Integra LifeSciences, Fast Track, Organon, Management

Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Key Points: 
  • Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
    Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
    Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies.
  • Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
  • Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.

700 LATINO LEADERS GATHER AT THE UNITED NATIONS TO AGREE ON THEIR COMMON AGENDA FOR A CRITICAL YEAR TO COME

Retrieved on: 
Wednesday, December 6, 2023
P&G, City National Bank, IBM, JPMorgan Chase, Advertising, Eli Lilly, Publicis, Hispanic, World Games, Sustainability, Bank, Synchrony, Heart, Telemundo, Anheuser-Busch, Summit, Yum! Brands, Content, Ashoka, GLAAD, Eye, Salesforce, Teach For America, Paramount, Revolution, Directory, Beam Suntory, AARP, For America, Workplace, SVP, Dallas Regional Chamber, Toronto-Dominion Bank, Safe space, USTA, Lyft, Ally, Gold medal, BMS, Walmart, Wells Fargo, Perindopril, NRG, Nightclub, Management, Bottled water, Latino, PepsiCo, Nationwide, Northwell Health, Aeroméxico, U.S. Bancorp, Organon, Coca-Cola

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- The We Are All Human Foundation  kicked off today the sixth Hispanic Leadership Summit, bringing together leaders from the public, private and non-profit sectors to create an annual agenda designed to advance the prosperity, power and progress of Latinos.

Key Points: 
  • The programming includes the implementation of playbooks, resources and toolkits to equip corporate America and other players to create robust Latino strategies.
  • "The Hispanic Leadership Summit has become an important part of how the We Are All Human Foundation works to unite the Latino community in order to advance the Latino path to progress.
  • The critical issues for our community remain changing perceptions and representation.
  • For two days, some of America's best corporations meet with community and non-profit organizations to share learnings and build consensus around priorities and programs.

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, November 9, 2023
Cream, Female, FDA, Bacterial vaginosis, Research, Human development, Trial of the century, Cooperative research and development agreement, Vaginal discharge, Food, Hot, Organon, Human services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, G&A, Progesterone, Phase 3, Quarter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Call, Development, NICHD, Webcast, Clinical trial, ID, Tamoxifen, FSAD, Bacteria, Hormone, NIH, Woman, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Patient, Bangladesh Technical Education Board, Pharmaceutical industry, Birth control, Bayer, Conference

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.
  • XACIATO™ provides a new therapeutic option for the millions of women suffering from bacterial vaginosis in the U.S.
  • Financial Highlights for the Quarter ended September 30, 2023
    Cash and cash equivalents: $13.8 million at September 30, 2023.
  • Daré will host a conference call and live webcast today, November 9, 2023, at 4:30 p.m. Eastern Time to review financial results for the quarter ended September 30, 2023 and to provide a company update.

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®

Retrieved on: 
Tuesday, November 7, 2023
FDA, Psoriasis, NYSE, Food, Organon, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OGN, Pharmacy, Head, Patient, Regulatory affairs, Pharmaceutical industry, Adalimumab

The sBLA was submitted to the FDA by Samsung Bioepis in August 2023.

Key Points: 
  • The sBLA was submitted to the FDA by Samsung Bioepis in August 2023.
  • We remain committed to helping more patients access biosimilar alternatives,” said Jon Martin, Head, US Biosimilars at Organon.
  • HADLIMA (adalimumab-bwwd) was first approved by the FDA in July 2019 as a low-concentration (40 mg/0.8 mL) formulation of prefilled syringe and prefilled autoinjector.
  • HADLIMA was introduced into the US commercial market on July 1, 2023 and is marketed by Organon.